Shionogi & Co.,Ltd. FY2027 Q1 Earnings Report

Quick View

Executive Summary

Although the integration of Torii Pharmaceutical and the former JT Pharmaceutical Business, together with the launch of the RADICAVA U.S. business, resulted in substantial increases in revenue and profit, it should be noted that the growth in net income was boosted by a temporary tax factor involving the recognition of a negative corporate income tax expense. Revenue was ¥163.31B (+63.7% year on year), while operating income was ¥66.91B (+90.6%, with an operating margin of 41.0%). Profit before tax was ¥73.74B (+59.2%), whereas consolidated profit for the quarter was ¥97.72B (+148.3%), and profit attributable to owners of the parent was ¥97.696B (+148.2%), both showing growth exceeding that of profit before tax. The primary drivers of revenue growth were the sharp expansions in domestic prescription pharmaceuticals (+137.3%) and overseas subsidiaries/exports (+196.6%), while the main drivers of profit growth were operating leverage, other income of ¥27.77B, and the recognition of a corporate income tax benefit.

Factors Affecting Results

【Revenue】Revenue was ¥163.31B, representing a substantial 63.7% year-on-year increase. By product category, domestic prescription pharmaceuticals contributed ¥33.5B (+137.3%, reflecting the integration effects of Torii Pharmaceutical, Radicava, and other products), overseas subsidiaries/exports contributed ¥42.2B (+196.6%, driven by the launch of the RADICAVA U.S. business and growth of cefiderocol in Europe and the United States), and royalty income contributed ¥80.1B (+25.3%, driven by the expansion of ViiV’s HIV franchise). Contract manufacturing, however, declined to ¥4.0B (△11.0%).

【Profit and Loss】Operating income was ¥66.91B (+90.6%), and the operating margin was 41.0%, improving by +5.8pt from 35.2% in the prior-year period, reflecting operating leverage from higher revenue. The gross margin was 81.1%, down from 87.7% in the prior year (87,464/99,781), with increased amortization of intangible assets acting as a drag. While profit before tax was limited to ¥73.74B (+59.2%), profit for the quarter increased to ¥97.72B (+148.3%), 32.6% above profit before tax. The primary reason for this divergence was a negative corporate income tax expense of ¥23.98B, representing a tax benefit, resulting in an unusually low effective tax rate of -32.5%. This appears to be strongly influenced by temporary factors and will require normalization over the full year. In conclusion, the Company achieved increases in both revenue and profit.

Segment Analysis

Although the Company omits segment information because it operates as a single business—prescription pharmaceuticals—royalty income was the largest category based on the sales composition by product group, at ¥80.1B and 49.2% of total revenue, and can be regarded as the core business. Royalty income increased 25.3% due to the expansion of ViiV’s HIV franchise and supported results as a stable source of revenue. The primary drivers of revenue growth were domestic prescription pharmaceuticals (+137.3%) and overseas subsidiaries/exports (+196.6%), both reflecting the integration of Torii Pharmaceutical and the former JT Pharmaceutical Business as well as the launch of the RADICAVA U.S. business. Although the breakdown of operating profit by product category is not disclosed, a difference in profit margins may exist between the domestic and overseas businesses, where amortization of intangible assets is concentrated, and royalty income, which carries a smaller amortization burden.

Key Financial Metrics

Profitability: ROE 5.5% (quarterly result), operating margin 41.0% (up +5.8pt from 35.2% in the prior year)
R&D investment ratio: 19.5% (R&D expenses of ¥31.79B/revenue, down -5.5pt year on year)
Cash flow quality: Operating CF/net income of 0.44x (¥43.11B/¥97.72B; cash backing for earnings is weak at below 1.0x), FCF of -¥380.62B
Investment efficiency: Capital expenditures/depreciation and amortization of 0.22x (¥4.60B/¥20.88B; tangible investment is restrained at below 1.0x, indicating an investment phase focused on M&A)
Financial soundness: Equity ratio of 66.7% (65.3% in the prior year), current ratio of 113.8% (current assets of ¥926.65B/current liabilities of ¥814.43B)

Cash Flow Analysis

Operating CF increased 5.0% year on year to ¥43.11B, but its ratio to profit for the quarter of ¥97.72B remained at 0.44x, indicating weak cash backing for earnings. Investing CF showed a substantial outflow of -¥423.73B, primarily due to ¥391.88B in expenditures for business acquisitions, while capital expenditures were limited to ¥4.60B. Financing CF was -¥34.14B, mainly reflecting dividend payments of ¥32.46B. Free CF (operating CF + investing CF) was substantially negative at -¥380.62B, and cash and cash equivalents decreased by -¥412.46B from the beginning of the period to ¥298.94B. This represents a temporary cash outflow associated with a large-scale M&A transaction, and cash generation should be monitored.

Earnings Quality

Profit for the quarter of ¥97.72B exceeded profit before tax of ¥73.74B by 32.6%, indicating a boost above recurring earnings capacity. The primary factor was the recognition of a negative corporate income tax expense of ¥23.98B, representing a tax benefit, resulting in an effective tax rate of -32.5%. Other income of ¥27.77B accounted for 17.0% of revenue, exceeding the 5% threshold, and, based on the information disclosed in the PDF, appears to be related to ViiV-related equity-method investment gains and items not reflected in purchase price allocation (PPA). Given that operating CF was only 0.44x net income, non-cash and non-recurring factors made a substantial contribution to earnings for the period, and normalization is expected toward the full year.

Earnings Forecast and Guidance

Progress toward the full-year forecasts of revenue of ¥700.0B, operating income of ¥220.0B, and net income of ¥210.0B was 23.3%, 30.4%, and 46.5%, respectively. Compared with standard progress (Q1 = 25%), revenue was broadly in line with the standard level (-1.7pt), operating income was slightly ahead (+5.4pt), and net income was substantially ahead (+21.5pt). The substantial acceleration in net income progress is believed to be primarily attributable to the temporary factor of recognizing a negative corporate income tax expense, and normalization toward the second half of the fiscal year is anticipated. Neither the earnings forecast nor the dividend forecast was revised in the current quarter.

Shareholder Returns

The full-year dividend forecast is ¥76 per share, implying a payout ratio of 30.8% based on forecast EPS of ¥246.79. Dividend payments during Q1 were ¥32.46B, representing the finalized dividend for the previous fiscal period, and no share repurchases were conducted. Since no share repurchases were made, the term “payout ratio” is appropriate. Dividend payments were covered within operating CF of ¥43.11B; however, FCF was negative due to the substantial investing CF outflow, and the sustainability of shareholder returns in the near term will depend on trends in operating cash flow generation.

Catalysts

【Short Term】Regulatory filings in Europe and Asia based on the results of Phase 3 trials for olorofim; FDA review of the pediatric indication for cefiderocol (PDUFA date: February 23, 2027); and the analyst briefing scheduled for August 3, 2026.

【Long Term】Announcement of the integrated pipeline, comprising a total of 65 products including Torii Pharmaceutical and the former JT Pharmaceutical Business, at the R&D briefing scheduled for November 18, 2026; development to extend the dosing intervals of ViiV’s long-acting injectable (LAI) formulations, transitioning to three-times-yearly and twice-yearly dosing; and expansion of the RADICAVA U.S. business and the XOCOVA U.S. rollout.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (pharma)

Profitability and Return

Both the operating margin and net profit margin substantially exceeded the industry median, placing the Company at the top end of the industry. However, it should be noted that the divergence in the net profit margin includes temporary factors such as the tax benefit.

Growth and Capital Efficiency

The revenue growth rate substantially exceeded the industry median and demonstrated exceptional growth within the industry.

※Source: Compiled by the Company

Risk Factors

1. Risk of reversal of temporary tax factors: Corporate income tax expense was negative at ¥23.98B for the period, representing a tax benefit, and the effective tax rate was -32.5%. Profit for the quarter of ¥97.72B exceeded profit before tax of ¥73.74B by 32.6%, and the EPS growth rate may slow as the tax rate normalizes over the full year.

2. Changes in asset composition and amortization/impairment risk associated with M&A: Intangible assets increased sharply by +198.9% from the end of the previous fiscal year (¥188.04B→¥562.12B), while goodwill increased +119.5% (¥29.22B→¥64.12B). Intangible assets reached 21.2% of total assets, and amortization of product-related intangible assets of ¥15.82B was recognized during the current period alone. Trends in future amortization expenses and impairment losses must therefore be monitored.

3. Cash flow and liquidity: Operating CF was ¥43.11B, only 0.44x profit for the quarter, indicating relatively weak cash backing for earnings. Primarily due to ¥391.88B in expenditures for business acquisitions, investing CF was substantially negative at -¥423.73B, and FCF was -¥380.62B. Bonds and borrowings of ¥660.0B are included in current liabilities, requiring close attention to liquidity and maturity management.

Key Earnings Highlights

1. The increases in revenue and profit were driven by the integration effects of Torii Pharmaceutical and the former JT Pharmaceutical Business as well as the launch of the RADICAVA U.S. business, with the operating margin improving +5.8pt year on year to 41.0%. Royalty income from ViiV’s HIV franchise, which accounted for 49.2% of the revenue mix, served as the core business supporting results.

2. Net income was reported at a level 32.6% above profit before tax, with the temporary tax factor of recognizing a negative corporate income tax expense contributing to the result. Depending on full-year tax rate trends, the net income growth rate may fluctuate toward the second half of the fiscal year.

3. Progress toward the full-year targets was ahead of the standard pace of 25%, with operating income at 30.4% and net income at 46.5%. However, given the substantial contribution from non-recurring income and tax factors, the extent of normalization in the first-half and full-year results will be a key focus going forward.

Theoretical Share Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson-type model with an explicit five-year fade period). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥2,289–¥2,427 for cost of equity ±1%; ¥2,349–¥2,367 for ω ±0.1.

Notes:

• Since net income progress toward the full-year forecast (47%) exceeds the standard level (25%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies with progress ahead of schedule tend to exceed forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Net assets as of the end of the quarter are used (there is a timing gap relative to the full-year forecast).

(Calculation model: Residual income model / Interest rate reference month: 2026-06 / This value does not forecast or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI through the integrated analysis of XBRL earnings summary data and PDF earnings presentation materials. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, and you should consult a professional as necessary.

---End of Report---